School of Medicine
Showing 61-80 of 165 Results
-
Ami J. Shah
Clinical Professor, Pediatrics - Stem Cell Transplantation
BioI joined Stanford University in 2015 as a Clinical Professor of Pediatrics in the Division of Hematology/ Oncology, Stem Cell Transplantation and Regenerative Medicine, having completed my training in Pediatric Hematology/ Oncology at Childrens Hospital Los Angeles. My areas of clinical expertise have been in the areas of transplantation for immune deficiencies and immune reconstitution post HSCT. I have been actively involved with the care and treatment of children with primary immune deficiencies and work with the Primary Immune Deficiencies Consortium (PIDTC). I am very interested in cellular therapies as a treatment modality for rare genetic diseases. I currently am the PI for several gene therapy trials at Stanford for various disorders including cerebral adrenoleukodystrophy (cALD), Sickle Cell Anemia, Thalassemia and Pyruvate Kinase Deficiency. My other main areas of research have been in studying the late effects of patients following stem cell transplantation, in specific the neurocognitive function post HSCT. I have been involved with several national committees addressing the late effects of HSCT within the ASBMT and COG.
In addition to my research work in stem cell transplantation, I have been actively involved with mentorship and graduate medical education. I am currently the Program Director for the Hematology/ Oncology Fellowship and serve as a mentor through the Pediatric Mentoring Group. -
Mona D. Shah, MD, MBA
Adjunct Clinical Associate Professor, Pediatrics - Hematology & Oncology
BioDr. Mona Shah is a pediatric hematologist-oncologist, who earned her MD degree at the University of Maryland in 2001. She completed both her categorical pediatrics and global health residencies in 2004, followed by a pediatric hematology-oncology fellowship in 2007. She earned her MS in Clinical Investigation as part of the Clinical Scientist Training Program (CSTP) at Baylor College of Medicine in 2011, and more recently, completed an Executive MBA at Rice University Jones School of Business in 2018.
Dr. Shah was an Associate Professor at Baylor College of Medicine (2007 - 2020) in both Pediatrics and Medicine, local site PI on a number of pediatric hemostasis/thrombosis clinical trials, and spent 10 years as an Associate Medical Director of Clinical Operations, Quality, and Safety at Texas Children’s Hospital, Houston, TX.
Dr. Shah joined Genentech (a Member of the Roche Group)’s Rare Blood Disorders Franchise (Product Development - Oncology-Hematology) in February 2020, quickly advancing to Lead Medical Director, where she served as Medical Monitor for 2 Phase III Clinical Trials (crovalimab in atypical hemolytic uremic syndrome, aHUS). She was also engaged with the Renal Franchise (I2O) in developing crovalimab in Lupus Nephritis (Phase I & II Clinical Trials in development), and with Human Factors/Pediatric Formulations Working Group on autoinjector devices and oral formulations.
After completing a rotation in Early Development Safety (EDS), she was promoted to Senior Medical Safety Director in Late Stage Product Development, and was appointed Safety Strategy Lead for giredestrant in early and metastatic breast, ovarian, and endometrial cancer global clinical trials. She has experience in innovative study designs (adaptive/multi-drug), with FDA/EMA pediatric investigational plans, and health authority interactions. In June 2023, she was appointed Pediatric Safety Lead, in collaboration with the iPODD Team, supporting safety for pediatric indications and devices, and serves as the Co-Chair of the Pediatric Safety Expert Group.
Dr. Shah has kept and completed a bucket list since she was 7 years old (keeps growing): Running wild bouldering/rock climbing as a child in the Shenandoah/Blue Ridge Mountains, swimming with dolphins/piranhas in the Amazon, climbing inside a volcano caldera in Iceland, snorkeling the Great Barrier Reef ... have passport/will travel!
Since July 2022, she has joined Stanford University School of Medicine, as an Adjunct Clinical Associate Professor in the Department of Pediatrics, Division of Hematology-Oncology, where she enjoys teaching MSII students, and at the bedside in the Lucille Packard Bass Center Hematology Clinic. Dr. Shah enjoys free time in her new home base near San Francisco, where she hosts her visiting parents, friends, and extended family. -
Sejal Shah
Clinical Assistant Professor, Pediatrics - Endocrinology and Diabetes
Current Research and Scholarly InterestsMy primary research interest is evaluating whether vitamin D supplementation can positively affect consequences of the metabolic syndrome in overweight and obese adolescents. Other research interests include evaluating the efficacy and biochemical profiles of various types of estrogen replacement in adolescent females.
-
Paul Sharek MD, MPH
Professor of Pediatrics (Hospital Medicine) at the Lucile Salter Packard Children's Hospital, Emeritus
Current Research and Scholarly InterestsResearch interests centered on hospital based quality of care improvement, and in particular pediatric patient safety. Areas of recent interest include developing practical tools to more accurately identify adverse medical events and to establish national rates of these adverse events. Additional areas of interest focus on developing the processes and systems to decrease the frequency of adverse drug events and adverse medical events at Children's hospitals in North America
-
Aditi Sharma
Basic Life Res Scientist, Pediatrics - General Pediatrics
Current Role at StanfordResearch Scientist
-
Seth Andrew Sharp
Postdoctoral Scholar, Endocrinology and Metabolism
BioSeth is a Postdoctoral Fellow in the Translational Genomics of Diabetes lab located at Stanford Research Park under the supervision of Professor Anna Gloyn. Seth completed a B.E. in Applied Mathematics before studying a PhD at the University of Exeter with Dr Richard Oram where he researched the use of genetics to predict common autoimmune disorders. Seth studied at the Alan Turing Institute in London where he used machine learning and artificial intelligence methods to predict autoimmunity and has worked collaboratively to improve screening of Type 1 diabetes from birth. Seth's postdoctoral studies focus on using genetic, transcriptomic and epigenetic data to understand the mechanisms by which both Type 1 and Type 2 diabetes occur in the human pancreas. He is also interested in ways to quantify genetic risk such as polygenic risk scores and their application in both research and clinic.
-
Gary M. Shaw
NICU Nurses Professor and Professor (Research), by courtesy, of Epidemiology and Population Health and of Obstetrics and Gynecology (Maternal Fetal Medicine)
Current Research and Scholarly InterestsPrimary research interests include 1) epidemiology of birth defects, 2) gene-environment approaches to perinatal outcomes, and 3) nutrition and reproductive outcomes.
-
Richard J. Shaw, M.D.
Professor of Psychiatry and Behavioral Sciences (Child & Adolescent Psychiatry) &, by courtesy, of Pediatrics
Current Research and Scholarly InterestsPsychological issues in medically ill children.
Medical posttraumatic stress disorder.
Treatment adherence.
Transplant psychiatry.
Pediatric oncology.
Forensic psychiatry. -
Xinshu She
Clinical Associate Professor, Pediatrics
Clinical Associate Professor, Pediatrics - General PediatricsCurrent Research and Scholarly InterestsMy current interests include global mental health promotion in underserved pediatric populations, including refugee health in US-Mexico borders, minority mental health in the US, and parental mental health in low-middle-income countries. I am also interested in physician wellness and Diversity and Inclusion.
-
Hiroyuki Shimada
Professor of Pathology and of Pediatrics
BioHiroyuki Shimada, MD, PhD, FRCPA (Hon), is Professor of Pathology and of Pediatrics at the Stanford University Medical Center. He was born in Tokyo, Japan, and completed MD (1973) and PhD (1982) at the Yokohama City University School of Medicine, Yokohama, Japan, and also completed his pathology training at the Children's Hospital (now the Nationwide Children’s Hospital) and the Ohio State University, Columbus, Ohio, USA (1988). Before moving to the Stanford University in 2019, he was Professor of Pathology (Clinical Scholar) at the University of Southern California Keck School of Medicine and working at the Children’s Hospital Los Angeles.
Dr. Shimada was Chair of the International Neuroblastoma Pathology Committee (1999-2017) and the founder of the International Neuroblastoma Pathology Classification (INPC). As Director of the COG (Children’s Oncology Group) Neuroblastoma Pathology Reference Laboratory (since 2001), he has been actively reviewing pathology samples of ~700 neuroblastoma cases per year from United States, Canada, Australia, and New Zealand. Pathology review results according to the INPC have been providing critical information for patient stratification and protocol assignment in the COG international neuroblastoma clinical trials. -
Andrew Young Shin
Clinical Professor, Pediatrics - Cardiology
Current Research and Scholarly InterestsSURF PROGRAM
The SURF program is an innovative collaboration between LPCH, Stanford University Hospital and the Stanford School of Engineering. The program has focused on improving quality and safety of patient care, improving hospital operations and promoting clinical effectiveness utilizing contemporary technologies such as machine learning, mathematical optimization, simulation and a variety of statistical, probabilistic and computational tools. The program has 2 independent funding mechanism to primarily improve patient care/hospital operations and improve academics for faculty within the department of Pediatrics at LPCH.
https://surf.stanford.edu/
CLINICAL EFFECTIVENESS
The Clinical Effectiveness (CE) Program is a funded program that aims to understand and improve unnecessary variation in healthcare delivery in order to optimize quality of care and reduce wasteful expenditures. The CE program has developed innovative programs such as Target Based Care, an award-winning intervention to reduce variation in hospital length of stay and currently a multi-center trial involving more than 20 hospitals in North America. In 2016, the CE program included the first CE fellowship program in a pediatric training program with 3 cycles of graduates. The CE program is supported by LPCH and a philanthropic gift by Susan Choe and Thomas Tobiason.
